CA3115448A1 - Glp-1 receptor antagonists - Google Patents
Glp-1 receptor antagonists Download PDFInfo
- Publication number
- CA3115448A1 CA3115448A1 CA3115448A CA3115448A CA3115448A1 CA 3115448 A1 CA3115448 A1 CA 3115448A1 CA 3115448 A CA3115448 A CA 3115448A CA 3115448 A CA3115448 A CA 3115448A CA 3115448 A1 CA3115448 A1 CA 3115448A1
- Authority
- CA
- Canada
- Prior art keywords
- compound according
- lysr
- syndrome
- ser
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1816639.7A GB201816639D0 (en) | 2018-10-12 | 2018-10-12 | GLP-1 Receptor Antagonist |
| GB1816639.7 | 2018-10-12 | ||
| PCT/GB2019/052915 WO2020074927A2 (en) | 2018-10-12 | 2019-10-14 | Glp-1 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3115448A1 true CA3115448A1 (en) | 2020-04-16 |
Family
ID=64397527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3115448A Pending CA3115448A1 (en) | 2018-10-12 | 2019-10-14 | Glp-1 receptor antagonists |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12441777B2 (https=) |
| EP (1) | EP3863661A2 (https=) |
| JP (1) | JP7492507B2 (https=) |
| CN (1) | CN113166206A (https=) |
| AU (1) | AU2019358324B2 (https=) |
| CA (1) | CA3115448A1 (https=) |
| GB (1) | GB201816639D0 (https=) |
| WO (1) | WO2020074927A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202011604D0 (en) * | 2020-07-27 | 2020-09-09 | Heptares Therapeutics Ltd | GLP-1 receptor antagonists |
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7399489B2 (en) | 1999-01-14 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Exendin analog formulations |
| CN100540565C (zh) | 2005-01-14 | 2009-09-16 | 无锡宏创医药科技有限公司 | 修饰的Exendins及其应用 |
| WO2007139941A2 (en) | 2006-05-26 | 2007-12-06 | Amylin Pharmaceuticals, Inc. | Composition and methods for treatment of congestive heart failure |
| WO2010032509A1 (ja) * | 2008-09-20 | 2010-03-25 | 国立大学法人京都大学 | 膵島イメージング用分子プローブ前駆体及びその使用 |
| WO2010120476A2 (en) | 2009-04-01 | 2010-10-21 | Amylin Pharmaceuticals, Inc. | N-terminus conformationally constrained glp-1 receptor agonist compounds |
| CN101870728A (zh) | 2009-04-23 | 2010-10-27 | 派格生物医药(苏州)有限公司 | 新型Exendin变体及其缀合物 |
| WO2011027584A1 (ja) * | 2009-09-04 | 2011-03-10 | 国立大学法人京都大学 | 膵島イメージング用分子プローブ及びその使用 |
| US9278146B2 (en) * | 2010-10-08 | 2016-03-08 | Kyoto University | Peptide derivative and use of the same |
| CN102532301B (zh) * | 2010-12-31 | 2014-09-03 | 上海医药工业研究院 | 一类新型的Exendin-4类似物及其制备方法 |
| GB201315335D0 (en) * | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| LT3297653T (lt) * | 2015-05-22 | 2022-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais |
-
2018
- 2018-10-12 GB GBGB1816639.7A patent/GB201816639D0/en not_active Ceased
-
2019
- 2019-10-14 US US17/284,351 patent/US12441777B2/en active Active
- 2019-10-14 JP JP2021520179A patent/JP7492507B2/ja active Active
- 2019-10-14 CN CN201980080295.9A patent/CN113166206A/zh active Pending
- 2019-10-14 EP EP19790753.8A patent/EP3863661A2/en active Pending
- 2019-10-14 WO PCT/GB2019/052915 patent/WO2020074927A2/en not_active Ceased
- 2019-10-14 CA CA3115448A patent/CA3115448A1/en active Pending
- 2019-10-14 AU AU2019358324A patent/AU2019358324B2/en active Active
-
2025
- 2025-06-26 US US19/251,101 patent/US20250368709A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019358324B2 (en) | 2025-05-22 |
| AU2019358324A1 (en) | 2021-04-22 |
| JP7492507B2 (ja) | 2024-05-29 |
| US12441777B2 (en) | 2025-10-14 |
| CN113166206A (zh) | 2021-07-23 |
| US20250368709A1 (en) | 2025-12-04 |
| US20210355186A1 (en) | 2021-11-18 |
| GB201816639D0 (en) | 2018-11-28 |
| WO2020074927A2 (en) | 2020-04-16 |
| JP2022504798A (ja) | 2022-01-13 |
| WO2020074927A3 (en) | 2020-12-17 |
| EP3863661A2 (en) | 2021-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250368709A1 (en) | Glp-1 receptor antagonists | |
| CN114349828B (zh) | Glp-1/胰高血糖素受体双重激动剂及其应用 | |
| AU2007319066B2 (en) | Selective glucagon-like-peptide-2 (GLP-2) analogues | |
| EP2552471B1 (en) | Novel peptides and methods for their preparation and use | |
| CN108348583B (zh) | 胰高血糖素受体激动剂 | |
| JP2006501820A (ja) | 修飾glp−1受容体アゴニストおよびそれらの薬理学的使用法 | |
| CN116143884B (zh) | 一类长效GLP-1/glucagon/GIP受体三重激动剂及其应用 | |
| AU2017252015A1 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| US20230279053A1 (en) | Glp-1 receptor antagonists | |
| CN115873096B (zh) | 一种胰高血糖素糖肽-1和胰高血糖素受体双重激动多肽及其应用 | |
| CA3175430A1 (en) | Oral glp receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED Effective date: 20240726 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240923 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240923 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240923 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241010 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241010 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241118 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241125 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250129 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250612 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250717 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250717 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250717 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250717 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250717 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250731 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251201 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260113 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260113 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260113 |